High-dose Dexamethasone Therapy as the Initial Treatment for Idiopathic Thrombocytopenic Purpura: Protocol for a Multicenter, Open-label, Single Arm Trial.
Acta Med Okayama
; 72(2): 197-201, 2018 Apr.
Article
em En
| MEDLINE
| ID: mdl-29674771
ABSTRACT
Standard therapy for idiopathic thrombocytopenic purpura (ITP) has not been established. We are conducting a multicenter, prospective trial to determine the efficacy and safety of short-term, high-dose dexamethasone therapy in ITP patients aged 18-80 years with platelet counts of <20, 000 /µL, or with <50, 000/ µL and bleeding symptoms. The primary endpoints of this trial are the proportion of responses (complete plus partial response) on day 180 (day 46+180) after the completion of the 46-day high-dose dexamethasone therapy. The results of this investigation of the effectiveness and safety of this regimen will be essential for the establishment of standard therapy for ITP.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Dexametasona
/
Púrpura Trombocitopênica Idiopática
/
Glucocorticoides
Tipo de estudo:
Clinical_trials
/
Guideline
Limite:
Adult
/
Aged
/
Humans
/
Middle aged
Idioma:
En
Revista:
Acta Med Okayama
Ano de publicação:
2018
Tipo de documento:
Article